Schizophrenie
Tóm tắt
Từ khóa
Tài liệu tham khảo
World Health Organization Mental health: Schizophrenia. http://www.who.int/mental_health/management/schizophrenia/en/ . Zugegriffen: 8. Okt. 2016
Oertel-Knöchel V, Bittner RA, Knöchel C, Prvulovic D, Hampel H (2011) Discovery and development of integrative biological markers for schizophrenia. Prog Neurobiol 95(4):686–702. https://doi.org/10.1016/j.pneurobio.2011.05.006
Statistische Bundesamt Gesundheitsberichterstattung des Bundes (2010) Heft 50. Statistische Bundesamt, Berlin
Adityanjee A, Aderibigbe Y, Theodoridis D, Vieweg RV (2002) Dementia praecox to schizophrenia:The first 100 years. Psychiatry Clin Neurosci 53:437–448
Bleuler E (1911) Dementia Praecox Oder Gruppe Der Schizophrenien. Nachdruck. edition diskord, Tübingen
Goddemeier C (2007) Eugen Bleuler – Den Menschen hinter der Psychose wiederfinden. Dtsch Arztebl 2007/5(5):225–226
Leucht S, Vauth R, Olbrich HM, Jäger M (2014) Schizophrenien und andere psychotische Störungen. In: Berger M (Hrsg) Psychische Erkrankungen – Klinik Und Therapie. 5. Aufl. Urban & Fischer Verlag/Elsevier GmbH, Jena, S 301–358
Gaebel W, Zielasek J (2015) Focus on psychosis. Dialogues Clin Neurosci 17(1):9–18 ( http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4421906&tool=pmcentrez&rendertype=abstract . Accessed March 29, 2016.)
Wölwer W, Lowe A, Frommann N (2014) Training sozial-kognitiver Funktionen – neue Ansätze zur Vermeidung psychosozialer Behinderungen bei schizophrenen Erkrankungen. Fortschr Neurol Psychiatr 82(4):203–209. https://doi.org/10.1055/s-0034-1366205
Jäger M, Strauß A, Frasch K, Becker T (2007) Konzeptuelle Grundlagen der operationalen Diagnostik in der Psychiatrie. Fortschr Neurol Psychiatr 75(8):478–483. https://doi.org/10.1055/s-2007-959236
Owen MJ, Sawa A, Mortensen PB (2016) Schizophrenia. Lancet 388(10039):86. https://doi.org/10.1016/S0140-6736(15)01121-6
Gaebel W, Zielasek J (2015) Schizophrenia in 2020: Trends in diagnosis and therapy. Psychiatry Clin Neurosci 69(11):661–673. https://doi.org/10.1111/pcn.12322
Tandon R, Gaebel W, Barch DM et al (2013) Definition and description of schizophrenia in the DSM-5. Schizophr Res 150(1):3–10. https://doi.org/10.1016/j.schres.2013.05.028
Falkai P (2015) Diagnostisches Und Statistisches Manual Psychischer Störungen – DSM-5 ®/American Psychiatric Association. Hogrefe, Göttingen, Bern, Wien (Dt. Ausg. Hrsg. von Peter Falkai Und Hans-Ulrich Wittchen)
Orlovska S, Pedersen MS, Benros ME, Mortensen PB, Agerbo E, Nordentoft M (2014) Head injury as risk factor for psychiatric disorders: a nationwide register-based follow-up study of 113,906 persons with head injury. Am J Psychiatry 171(4):463–469. https://doi.org/10.1176/appi.ajp.2013.13020190
Aleman A, Kahn RS, Selten J (2003) Sex Differences in the Risk of Schizophrenia. Arch Gen Psychiatry 60:565–571
Castle DJ, Murray RM (1991) The neurodevelopmental basis of sex differences. Psychol Med 21(3):565–575. https://doi.org/10.1017/S0033291700022194
Stilo SA, Murray RM (2010) The epidemiology of schizophrenia: replacing dogma with knowledge. Dialogues Clin Neurosci 12(3):305–315 ( http://www.ncbi.nlm.nih.gov/pubmed/20954427 .)
Schooler NR, Buchanan RW, Laughren T et al (2015) Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms. Schizophr Res 162(1–3):169–174. https://doi.org/10.1016/j.schres.2014.12.001
Böök JA, Wetterberg L, Modrzewska K (1978) Schizophrenia in a North Swedish geographical isolate, 1900–1977. Epidemiology, genetics and biochemistry. Clin Genet 14(6):373–394. https://doi.org/10.1111/j.1399-0004.1978.tb02105.x
Torrey EF, McGuire M, O’Hare A, Walsh D, Spellman MP (1984) Endemic psychosis in western Ireland. Am J Psychiatry 141(8):966–970. https://doi.org/10.1176/ajp.141.8.966
Väisänen E (1975) Psychiatric disorders in Finland. Acta Psychiatr Scand 52(S263):22–33. https://doi.org/10.1111/j.1600-0447.1975.tb02281.x
Folnegovic Z, Folnegovic-Smalc V (1992) Schizophrenia in Croatia: interregional differences in prevalence and a comment on constant incidence. J Epidemiol Community Health 46(3):248–255. https://doi.org/10.1136/jech.46.3.248
Goodman AB (1994) Medical conditions in Ashkenazi schizophrenic pedigrees. Schizophr Bull 20(3):507–517 ( http://www.ncbi.nlm.nih.gov/pubmed/7973467 )
Thara R, Eaton WW (1996) Outcome of schizophrenia: the Madras longitudinal study. Aust N Z J Psychiatry 30(4):516–522 ( http://www.ncbi.nlm.nih.gov/pubmed/8887703 . Accessed March 31, 2016)
Gottesman II, Erlenmeyer-Kimling L (2001) Family and twin strategies as a head start in defining prodromes and endophenotypes for hypothetical early-interventions in schizophrenia. Schizophr Res 51(1):93–102. https://doi.org/10.1016/S0920-9964(01)00245-6
McGrath JJ, Petersen L, Agerbo E, Mors O, Mortensen PB, Pedersen CB (2014) A comprehensive assessment of parental age and psychiatric disorders. JAMA Psychiatry 71(3):301–309. https://doi.org/10.1001/jamapsychiatry.2013.4081
Verdoux H, Geddes JR, Takei N et al (1997) Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Am J Psychiatry 154(9):1220–1227. https://doi.org/10.1176/ajp.154.9.1220
Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361(9369):1581–1589. https://doi.org/10.1016/S0140-6736(03)13306-5
Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM (2012) Meta-analysis of the association of urbanicity with schizophrenia. Schizophr Bull 38(6):1118–1123. https://doi.org/10.1093/schbul/sbs096
Agid O, Shapira B, Zislin J et al (1999) Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol Psychiatry 4(2):163–172. https://doi.org/10.1038/sj.mp.4000473
Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR (2014) The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry 14(1):75. https://doi.org/10.1186/1471-244X-14-75
Radhakrishnan R, Wilkinson ST, Samuel D’Souza DC (2014) Gone to pot—a review of the association between cannabis and psychosis. Front Psychiatry 5(May):54. https://doi.org/10.3389/fpsyt.2014.00054
Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Murray RM (2005) Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet 136B(1):87–91. https://doi.org/10.1002/ajmg.b.30187
Andréasson S, Engström A, Allebeck P, Rydberg U (1987) Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 330(8574):1483–1486. https://doi.org/10.1016/S0140-6736(87)92620-1
van Os J, Rutten BP, Poulton R (2008) Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 34(6):1066–1082. https://doi.org/10.1093/schbul/sbn117
Dazzan P, Arango C, Fleischacker W et al (2015) Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. Schizophr Bull 41(3):1–10. https://doi.org/10.1093/schbul/sbv024
Dazzan P, Soulsby B, Mechelli A et al (2012) Volumetric abnormalities predating the onset of schizophrenia and affective psychoses: an MRI study in subjects at ultrahigh risk of psychosis. Schizophr Bull 38(5):1083–1091. https://doi.org/10.1093/schbul/sbr035
Meyer-Lindenberg A (2011) Neuroimaging and the question of neurodegeneration in schizophrenia. Prog Neurobiol 95(4):514–516. https://doi.org/10.1016/j.pneurobio.2011.07.007
Lieberman JA (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46(6):729–739 ( http://www.ncbi.nlm.nih.gov/pubmed/10494440 . Accessed April 2, 2016)
Weinberger DR, McClure RK (2002) Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry 59(6):553–558 ( http://www.ncbi.nlm.nih.gov/pubmed/12044198 . Accessed April 2, 2016)
Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M (2009) Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19(2):220–230. https://doi.org/10.1016/j.conb.2009.05.001
Do KQ, Trabesinger AH, Kirsten-Krüger M et al (2001) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12(10):3721–3728. https://doi.org/10.1046/j.1460-9568.2000.00229.x
Tseng K‑Y, O’Donnell P (2007) Dopamine modulation of prefrontal cortical Interneurons changes during adolescence. Cereb Cortex 17(5):1235–1240. https://doi.org/10.1093/cercor/bhl034
Needham E, Zandi MS (2014) Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer’s disease, traumatic brain injury and schizophrenia. j Neurol 261(10):2037–2042. https://doi.org/10.1007/s00415-014-7473-x
Müller N, Schwarz MJ (2008) A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci 258(Suppl):97–106. https://doi.org/10.1007/s00406-008-2012-3
Hanson DR, Gottesman II (2005) Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 6(1):1–17. https://doi.org/10.1186/1471-2350-6-7
Looijestijn J, Blom JD, Aleman A, Hoek HW, Goekoop R (2015) An integrated network model of psychotic symptoms. Neurosci Biobehav Rev 59:238–250. https://doi.org/10.1016/j.neubiorev.2015.09.016
Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull 35(3):549–562. https://doi.org/10.1093/schbul/sbp006
Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276(5321):2048–2050 ( http://www.ncbi.nlm.nih.gov/pubmed/9197269 . Accessed April 3, 2016)
Zammit S, Moore THM, Lingford-Hughes A et al (2008) Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 193(5):357–363. https://doi.org/10.1192/bjp.bp.107.046375
Keshavan MS, Nasrallah HA, Tandon R (2011) Schizophrenia, „Just the Facts“ 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res 127(1–3):3–13. https://doi.org/10.1016/j.schres.2011.01.011
Benes F (2001) GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder. Neuropsychopharmacology 25(1):1–27. https://doi.org/10.1016/S0893-133X(01)00225-1
Carter CJ (2006) Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 86(1–3):1–14. https://doi.org/10.1016/j.schres.2006.05.023
Moghaddam B, Javitt D (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37(1):4–15. https://doi.org/10.1038/npp.2011.181
Insel TR (2010) Rethinking schizophrenia. Nature 468(7321):187–193. https://doi.org/10.1038/nature09552
Ort EP (2001) The World Health Report : 2001 : Mental Health : New Understanding, New Hope. WHO, Geneva. ISBN 978-9241562010
Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64(1):393–406. https://doi.org/10.1146/annurev-med-050911-161504
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41. https://doi.org/10.1016/S0140-6736(08)61764-X
Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962. https://doi.org/10.1016/S0140-6736(13)60733-3
Leucht S, Heres S, Kissling W, Davis J (2013) Pharmacological treatment of schizophrenia. Fortschr Neurol Psychiatr 81(5):e1–e13. https://doi.org/10.1055/s-0033-1335405
Gaebel W, Falkai P (1998) S3-Behandlungsleitlinie Schizophrenie: Kurzversion Bd. 1. Steinkopff, Darmstadt, S 184–233
Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168(6):603–609. https://doi.org/10.1176/appi.ajp.2011.10081224
Heres S, Lambert M, Vauth R (2014) Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry 29(S2):1409–1413. https://doi.org/10.1016/S0924-9338(14)70001-X
Leucht S, Tardy M, Komossa K et al (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379(9831):2063–2071. https://doi.org/10.1016/S0140-6736(12)60239-6
Stieglitz R‑D, Vauth R (2005) Verhaltenstheoretische Konzepte in der Ätiologie schizophrener Symptome. Fortschr Neurol Psychiatr 73(Sonderheft 1):60–65. https://doi.org/10.1055/s-2005-915545
Puschner B, Vauth R, Jacobi F, Becker T (2006) Bedeutung von Psychotherapie in der Versorgung von Menschen mit schizophrenen Störungen in Deutschland. Nervenarzt 77(11):1301–1309. https://doi.org/10.1007/s00115-006-2102-2
Dickerson FB, Lehman AF (2006) Evidence-based psychotherapy for schizophrenia. J Nerv Ment Dis 194(1):3–9. https://doi.org/10.1097/01.nmd.0000195316.86036.8a
Mojtabai R, Nicholson RA, Carpenter BN (1998) Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies. Schizophr Bull 24(4):569–587 ( http://www.ncbi.nlm.nih.gov/pubmed/9853790 . Accessed April 4, 2016)
Huhn M, Tardy M, Spineli LM et al (2014) Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry 71(6):706–715. https://doi.org/10.1001/jamapsychiatry.2014.112
Mueser KT, Deavers F, Penn DL, Cassisi JE (2013) Psychosocial treatments for schizophrenia. Annu Rev Clin Psychol 9(1):465–497. https://doi.org/10.1146/annurev-clinpsy-050212-185620
Juckel G, Morosini PL (2008) The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry 21(6):630–639. https://doi.org/10.1097/YCO.0b013e328314e144
Tharyan P, Adams CE (2005) Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD000076.pub2
Schultze-Lutter F, Ruhrmann S, Hoyer C, Klosterkötter J, Leweke FM (2007) The initial prodrome of schizophrenia: different duration, different underlying deficits? Compr Psychiatry 48(5):479–488. https://doi.org/10.1016/j.comppsych.2007.04.001
Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009) Psychiatric comorbidities and schizophrenia. Schizophr Bull 35(2):383–402. https://doi.org/10.1093/schbul/sbn135
Lang FU, Kösters M, Lang S, Becker T, Jäger M (2012) Psychopathological long-term outcome of schizophrenia—a review. Acta Psychiatr Scand 127(3):173–182. https://doi.org/10.1111/acps.12030
Hahlweg K, Dose M (2005) Schizophrenie. Hogrefe, Göttingen ; Bern ; Toronto ; Seattle
Ban TA (2007) Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat 3(4):495–500
Laursen TM, Nordentoft M, Mortensen PB (2014) Excess early mortality in schizophrenia. Annu Rev Clin Psychol 10(1):425–448. https://doi.org/10.1146/annurev-clinpsy-032813-153657
Saha S, Chant D, Welham J, McGrath J (2006) A systematic review of mortality in individuals with schizophrenia: preliminary results. Aust N Z J Psychiatry 40(2):A134
Melle I, Larsen TK, Haahr U et al (2008) Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry 65(6):634–640. https://doi.org/10.1001/archpsyc.65.6.634
Golay P, Alameda L, Baumann P et al (2016) Duration of untreated psychosis: Impact of the definition of treatment onset on its predictive value over three years of treatment. J Psychiatr Res 77:15–21. https://doi.org/10.1016/j.jpsychires.2016.02.017
Wölwer W, Baumann A, Bechdolf A et al (2006) The German Research Network on Schizophrenia—impact on the management of schizophrenia. Dialogues Clin Neurosci 8(1):115–121 ( http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3181752&tool=pmcentrez&rendertype=abstract . Accessed March 29, 2016)